TCM
GNMX

Teza Capital Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Teza Capital Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-24,160
Closed -$45K – 446
2017
Q1 		$45K Buy
+24,160
New +$109K 0.01% 491

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Teza Capital Management's GNMX Position: Q2 2017 in Review

Teza Capital Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 24,160 shares — an estimated $45K sold.

Teza Capital Management first reported a position in GNMX in Q1 2017 and held it in 1 quarter. The position peaked at $45K in Q1 2017. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • Teza Capital Management reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • Teza Capital Management sold 24,160 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $45K.
  • Teza Capital Management first reported a position in Aevi Genomic Medicine Inc in Q1 2017 and held it in 1 quarter.
  • Teza Capital Management's Aevi Genomic Medicine Inc position peaked at $45K in Q1 2017.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Teza Capital Management's 13F filing for Q2 2017.